IL-37-a putative therapeutic agent in cardiovascular diseases.
QJM
; 115(11): 719-725, 2022 Nov 14.
Article
in En
| MEDLINE
| ID: mdl-33486516
ABSTRACT
Although it is a member of the Interleukin (IL)-1 family, IL-37 is unique in that it has wide-ranging anti-inflammatory characteristics. It was originally thought to prevent IL-18-mediated inflammation by binding to the IL-18-binding protein. However, upon discovery that it binds to the orphan receptor, IL-1R8, further studies have revealed an expanded role of IL-37 to include several intracellular and extracellular pathways that affect various aspects of inflammation. Its potential role specifically in cardiovascular diseases (CVD) stemmed initially from the discovery of elevated plasma IL-37 levels in human patients with acute coronary syndrome and atrial fibrillation. Other studies using mouse models of ischemia/reperfusion injury, vascular calcification and myocardial infarction have revealed that IL-37 can have a beneficial role in these conditions. This review will explore recent research on the effects of IL-37 on the pathogenesis of CVD.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Receptors, Interleukin-1
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
QJM
Journal subject:
MEDICINA
Year:
2022
Document type:
Article
Affiliation country:
United States